AU2004283093B2 - Compounds and compositions as protein kinase inhibitors - Google Patents

Compounds and compositions as protein kinase inhibitors Download PDF

Info

Publication number
AU2004283093B2
AU2004283093B2 AU2004283093A AU2004283093A AU2004283093B2 AU 2004283093 B2 AU2004283093 B2 AU 2004283093B2 AU 2004283093 A AU2004283093 A AU 2004283093A AU 2004283093 A AU2004283093 A AU 2004283093A AU 2004283093 B2 AU2004283093 B2 AU 2004283093B2
Authority
AU
Australia
Prior art keywords
methyl
amide
carboxylic acid
pyrrolo
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004283093A
Other languages
English (en)
Other versions
AU2004283093A1 (en
Inventor
Qiang Ding
Nathanael Schiander Gray
Bing Li
Yi Liu
Tetsuo Uno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Publication of AU2004283093A1 publication Critical patent/AU2004283093A1/en
Application granted granted Critical
Publication of AU2004283093B2 publication Critical patent/AU2004283093B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2004283093A 2003-08-28 2004-08-27 Compounds and compositions as protein kinase inhibitors Ceased AU2004283093B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49853203P 2003-08-28 2003-08-28
US60/498,532 2003-08-28
PCT/US2004/027997 WO2005039486A2 (en) 2003-08-28 2004-08-27 Compounds and compositions as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2004283093A1 AU2004283093A1 (en) 2005-05-06
AU2004283093B2 true AU2004283093B2 (en) 2009-02-26

Family

ID=34519982

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004283093A Ceased AU2004283093B2 (en) 2003-08-28 2004-08-27 Compounds and compositions as protein kinase inhibitors

Country Status (9)

Country Link
US (2) US7338957B2 (cg-RX-API-DMAC7.html)
EP (1) EP1658290A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007504159A (cg-RX-API-DMAC7.html)
CN (1) CN100439365C (cg-RX-API-DMAC7.html)
AU (1) AU2004283093B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414049A (cg-RX-API-DMAC7.html)
CA (1) CA2536535A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06002347A (cg-RX-API-DMAC7.html)
WO (1) WO2005039486A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
PL1891066T3 (pl) * 2005-05-13 2011-05-31 Irm Llc Związki i kompozycje jako inhibitory kinazy białkowej
EP1999249B8 (en) * 2006-03-30 2012-02-15 The University Court Of The University of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
KR20090023561A (ko) 2006-04-07 2009-03-05 노파르티스 아게 ａ) 피리미딜아미노벤즈아미드 화합물과 ｂ) Ｔｈｒ３１５Ｉｌｅ 키나제 억제제를 포함하는 조합물
WO2008147831A1 (en) * 2007-05-23 2008-12-04 Smithkline Beecham Corporation Anthranilamides
CA2949336C (en) 2007-08-02 2018-11-06 Lei Zhu Process for the synthesis of e1 activating enzyme inhibitors
WO2009020990A1 (en) * 2007-08-08 2009-02-12 Smithkline Beecham Corporation 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] benzamide derivatives as igf-1r inhibitors for the treatment of cancer
EA019869B1 (ru) * 2007-11-28 2014-06-30 Дана Фарбер Кансер Инститьют, Инк. Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения
JP2011510004A (ja) * 2008-01-22 2011-03-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング タンパク質キナーゼ阻害剤及びその使用
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
UA108986C2 (uk) 2009-05-14 2015-07-10 Мілленніум Фармасьютікалз, Інк. Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-[(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло[2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти)
US8728763B2 (en) 2009-08-11 2014-05-20 Response Genetics Methods, primers, probes and kits useful for the detection of BRAF mutations
EA201391626A1 (ru) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN104876879B (zh) * 2015-04-14 2018-05-18 中国科学院合肥物质科学研究院 一种bcr-abl激酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT831829E (pt) * 1995-06-07 2003-12-31 Pfizer Derivados de pirimidina heterociclicos de aneis fundidos
WO2000017203A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines as protein kinase inhibitors
JP2003518123A (ja) * 1999-12-21 2003-06-03 スージェン・インコーポレーテッド ４−置換７−アザ−インドリン−２−オンおよびその蛋白質キナーゼ阻害剤としての使用
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2003009852A1 (en) * 2001-07-24 2003-02-06 Merck & Co., Inc. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
US7338957B2 (en) 2008-03-04
CN100439365C (zh) 2008-12-03
CA2536535A1 (en) 2005-05-06
EP1658290A2 (en) 2006-05-24
CN1842529A (zh) 2006-10-04
AU2004283093A1 (en) 2005-05-06
BRPI0414049A (pt) 2006-10-24
WO2005039486A2 (en) 2005-05-06
EP1658290A4 (en) 2009-04-15
US20050159391A1 (en) 2005-07-21
WO2005039486A3 (en) 2006-03-16
MXPA06002347A (es) 2006-05-19
JP2007504159A (ja) 2007-03-01
US20080108616A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
US20080108616A1 (en) Compounds and compositions as protein kinase inhibitors
US8101608B2 (en) Compounds and compositions as protein kinase inhibitors
US8183248B2 (en) Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors
AU2006227790B2 (en) Compounds and compositions as protein kinase inhibitors
JP6599983B2 (ja) カルバゾール誘導体
KR102345381B1 (ko) 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
WO2004089286A2 (en) Novel compounds and compositions as protein kinase inhibitors
CA2619365A1 (en) Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
IL175572A (en) Condensed heterocycles, jak selective kinase inhibitors and pharmaceutical compositions comprising them
CN101166732B (zh) 氰基吡啶衍生物及其作为药物的应用
US20100168182A1 (en) Compounds and compositions as kinase inhibitors
US20170233395A1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
JP2016526545A (ja) スルホキシイミン置換キナゾリンならびにｍｎｋ１および／またはｍｎｋ２キナーゼ阻害薬としてのその使用
CN117561244A (zh) 异吲哚啉酮类化合物及其用途
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
US7125997B2 (en) Differential tumor cytotoxicity compounds and compositions
AU2006275849A1 (en) 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
AU2005258266A1 (en) Compounds and compositions as protein kinase inhibitors
CN101056632B (zh) 用作蛋白激酶抑制剂的化合物和组合物
US10550125B2 (en) Prodrugs of imidazotriazine compounds as CK2 inhibitors
CN101103031B (zh) 用于治疗增生性疾病的吡咯并嘧啶衍生物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired